diphenylcarbazone: sensitive reagent for Hg, for which it gives blue color; structure
ID Source | ID |
---|---|
PubMed CID | 10860 |
CHEMBL ID | 79409 |
SCHEMBL ID | 1057265 |
SCHEMBL ID | 1551533 |
MeSH ID | M0046051 |
Synonym |
---|
(e)-n',2-diphenyldiazenecarbohydrazide |
CHEMBL79409 , |
diazenecarboxylic acid, 2-phenyl-, 2-phenylhydrazide |
4-16-00-00017 (beilstein handbook reference) |
diphenylcarbazone |
diazenecarboxylic acid, phenyl-, 2-phenylhydrazide |
einecs 208-698-0 |
1,5-diphenylcarbazone |
phenyldiazenecarboxylic acid 2-phenylhydrazide |
brn 0959475 |
(phenylazo)formic acid 2-phenylhydrazide |
formic acid, (phenylazo)-, 2-phenylhydrazide |
538-62-5 |
sym-diphenylcarbazone |
D0881 |
1-anilino-3-phenyliminourea |
bdbm50071644 |
(e)-n'',2-diphenyldiazenecarbohydrazide |
AKOS003273042 |
AKOS024348870 |
STL280245 |
FT-0606976 |
diphenylcarbazone, (e)- |
diphenylcarbazone (e)-form |
diphenylcarbazone [mi] |
96YS88318X , |
diazenecarboxylic acid, phenyl-, 2-phenylhydrazide, (1e)- |
SCHEMBL1057265 |
diazenecarboxylic acid, phenyl-, 2-phenylhydrazide, (z)- |
diphenylcarbazone z-form [mi] |
119295-40-8 |
diphenylcarbazone, (z)- |
5UYJ4R0D5T , |
unii-5uyj4r0d5t |
1,5-diphenylcarbazone (for colorimetry tests) |
SCHEMBL1551533 |
DTXSID5060225 |
diazenecarbohydrazonic acid, n,2-diphenyl- |
3-hydroxy-1,5-diphenylformazan |
n',2-diphenyldiazenecarbohydrazide # |
phenylazoformic acid 2-phenylhydrazide |
hydrazinecarboxamide, 2-phenyl-n-(phenylimino)- |
ZFWAHZCOKGWUIT-BMRADRMJSA-N |
119295-41-9 |
unii-96ys88318x |
mfcd00003024 |
CS-0132463 |
diphenylcarbazone, p.a. |
diphenylcarbazon |
(e)-1,5-diphenylcarbazone |
Q1227136 |
H11948 |
Q27262902 |
Q27271938 |
(z)-diphenylcarbazone |
diphenylcarbazone (contains diphenylcarbazide) |
(e)-1-(phenylamino)-3-(phenylimino)urea |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Prothrombin | Homo sapiens (human) | Ki | 1.7000 | 0.0000 | 0.7846 | 9.0000 | AID219611 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
lipopolysaccharide binding | Prothrombin | Homo sapiens (human) |
serine-type endopeptidase activity | Prothrombin | Homo sapiens (human) |
signaling receptor binding | Prothrombin | Homo sapiens (human) |
calcium ion binding | Prothrombin | Homo sapiens (human) |
protein binding | Prothrombin | Homo sapiens (human) |
growth factor activity | Prothrombin | Homo sapiens (human) |
heparin binding | Prothrombin | Homo sapiens (human) |
thrombospondin receptor activity | Prothrombin | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
external side of plasma membrane | Prothrombin | Homo sapiens (human) |
collagen-containing extracellular matrix | Prothrombin | Homo sapiens (human) |
extracellular region | Prothrombin | Homo sapiens (human) |
extracellular space | Prothrombin | Homo sapiens (human) |
endoplasmic reticulum lumen | Prothrombin | Homo sapiens (human) |
Golgi lumen | Prothrombin | Homo sapiens (human) |
plasma membrane | Prothrombin | Homo sapiens (human) |
extracellular exosome | Prothrombin | Homo sapiens (human) |
blood microparticle | Prothrombin | Homo sapiens (human) |
collagen-containing extracellular matrix | Prothrombin | Homo sapiens (human) |
extracellular space | Prothrombin | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID219611 | Dissociation constant was evaluated by competitive inhibition of alpha-thrombin using the method of Dixon enzyme assay. | 1998 | Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18 | Templates for design of inhibitors for serine proteases: application of the program DOCK to the discovery of novel inhibitors for thrombin. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (27.27) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 5 (45.45) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |